Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH — Clinical Trial Site

10 Registered trials

2 Currently recruiting

Organisation

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Location

Frankfurt Am Main, Germany

Identifier

ORG-100013405

Address

Steinbacher Hohl 2-26, Praunheim, 60488, Germany

Departments

-
Institut für Klinisch-Onkologische Forschung
Institut für klinisch-onkologische Forschung (IKF)
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest
institute for clinical oncological research
Krankenhaus Nordwest, Steinbacher Hohl 2-26
NA
Thoraxonkologie

Clinical trials at this site (10)

Search interface

A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu… Pending

2024-517561-16-00 non-small cell lung cancer 4
Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 metastatic colorectal cancer 5
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone:… Recruiting

2023-503558-10-00 oligometastatic pancreatic cancer 5 2023-10-13
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended

2022-502267-37-00 metastatic colorectal cancer 9 2023-07-17
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 5 2019-05-20